TY - JOUR
T1 - Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors
AU - Pellissier, Lucie P.
AU - Sallander, Jessica
AU - Campillo, Mercedes
AU - Gaven, Florence
AU - Queffeulou, Emilie
AU - Pillot, Marion
AU - Dumuis, Aline
AU - Claeysen, Sylvie
AU - Bockaert, Joël
AU - Pardo, Leonardo
PY - 2009/4/1
Y1 - 2009/4/1
N2 - The extended classic ternary complex model predicts that a G protein-coupled receptor (GPCR) exists in only two interconvertible states: an inactive R, and an active R*. However, different structural active R* complexes may exist in addition to a silent inactive R ground state (Rg). Here we demonstrate, in a cellular context, that several R* states of 5-hydroxytrypta-mine-4 (5-HT4) receptors involve different side-chain conformational toggle switches. Using site-directed mutagenesis and molecular modeling approaches, we show that the basal constitutive receptor (R*basal) results from stabilization of an obligatory double toggle switch (Thr3.36 from inactive g-to active g+ and Trp6.48 from inactive g+ to active t). Mutation of either threonine or tryptophan to alanine resulted in a lowering of the activity of the R*basal similar to the Rg. The T3.36A mutation shows that the Thr3.36 toggle switch plays a minor role in the stabilization of R* induced by 5-HT (R*-5-HT) and BIMU8 (R*-BIMU8) and is fully required in the stabilization of R* induced by (S)-zacopride, cisapride, and 1-(4-amino-5-chloro-2-methoxy-phenyl)-3-(1-butyl-4-piperidinyl)-1-propanone (RS 67333) (R*-benzamides). Thus, benzamides stabilize R*-benzamides by forming a specific hydrogen bond with Thr3.36 in the active g +conformation. Conversely, R*-BIMU8 was probably the result of a direct conformational transition of Trp6.48 from inactiveg+ to active t by hydrogen bonding of this residue to a carboxyl group of BIMU8. We were surprised that the Trp6.48 toggle switch was not necessary for receptor activation by the natural agonist 5-HT. R*-5-HT is probably attained through other routes of activation. Thus, different conformational arrangements occur during stabilization of R*basal, R*-5-HT, R*-benzamides, and R*-BIMU8.Copyright © 2009 The American Society for Pharmacology and Experimental Therapeutics.
AB - The extended classic ternary complex model predicts that a G protein-coupled receptor (GPCR) exists in only two interconvertible states: an inactive R, and an active R*. However, different structural active R* complexes may exist in addition to a silent inactive R ground state (Rg). Here we demonstrate, in a cellular context, that several R* states of 5-hydroxytrypta-mine-4 (5-HT4) receptors involve different side-chain conformational toggle switches. Using site-directed mutagenesis and molecular modeling approaches, we show that the basal constitutive receptor (R*basal) results from stabilization of an obligatory double toggle switch (Thr3.36 from inactive g-to active g+ and Trp6.48 from inactive g+ to active t). Mutation of either threonine or tryptophan to alanine resulted in a lowering of the activity of the R*basal similar to the Rg. The T3.36A mutation shows that the Thr3.36 toggle switch plays a minor role in the stabilization of R* induced by 5-HT (R*-5-HT) and BIMU8 (R*-BIMU8) and is fully required in the stabilization of R* induced by (S)-zacopride, cisapride, and 1-(4-amino-5-chloro-2-methoxy-phenyl)-3-(1-butyl-4-piperidinyl)-1-propanone (RS 67333) (R*-benzamides). Thus, benzamides stabilize R*-benzamides by forming a specific hydrogen bond with Thr3.36 in the active g +conformation. Conversely, R*-BIMU8 was probably the result of a direct conformational transition of Trp6.48 from inactiveg+ to active t by hydrogen bonding of this residue to a carboxyl group of BIMU8. We were surprised that the Trp6.48 toggle switch was not necessary for receptor activation by the natural agonist 5-HT. R*-5-HT is probably attained through other routes of activation. Thus, different conformational arrangements occur during stabilization of R*basal, R*-5-HT, R*-benzamides, and R*-BIMU8.Copyright © 2009 The American Society for Pharmacology and Experimental Therapeutics.
U2 - 10.1124/mol.108.053686
DO - 10.1124/mol.108.053686
M3 - Article
SN - 0026-895X
VL - 75
SP - 982
EP - 990
JO - Molecular Pharmacology
JF - Molecular Pharmacology
ER -